| 引用本文:姜振蕊1，李泉星2，曲霞1.参一胶囊联合吉非替尼对晚期非小细胞肺癌患者外周血清基质金属蛋白酶-9的影响[J].世界中医药,2018,(08):. |
|
| 参一胶囊联合吉非替尼对晚期非小细胞肺癌患者外周血清基质金属蛋白酶-9的影响 |
| Effects of Shenyi Capsule Combined with Gefitinib on Peripheral Serum MMP-9 in Patients with Advanced Non-small Cell Lung Cancer |
| 投稿时间：2018-01-11 |
| DOI：10.3969/j.issn.1673-7202.2018.08.016 |
| 中文关键词: 参一胶囊 吉非替尼 晚期 非小细胞肺癌 基质金属蛋白酶-9 |
| English Keywords:Shenyi capsule Gefitinib Advanced Non-small cell lung cancer MMP-9 |
| 基金项目:山东省高等学校科技计划项目（J15LK02） |
|
| 摘要点击次数: 869 |
| 全文下载次数: 753 |
| 中文摘要: |
| 目的：观察参一胶囊联合吉非替尼对晚期非小细胞肺癌（NSCLC）患者外周血清基质金属蛋白酶-9（MMP-9）的影响。方法：选取2015年3月至2017年1月东营市鸿港医院肿瘤科收治入院的NSCLC患者126例，随机分为观察组（参一胶囊+吉非替尼）与对照组（吉非替尼），每组63例。治疗60 d后，比较2组临床疗效情况、治疗前后血清MMP-9及组织抑制物-1（TIMP-1）表达情况；采用生命质量评估（QOL）量表评价患者治疗后生命质量改善情况，并参考WHO常见化疗药物毒性反应分级标准，记录患者与用药相关的严重不良反应发生情况。结果：观察组患者总缓解率63.93%，对照组的总缓解率为55.74%，2组间总缓解率差异无统计学意义（P>0.05）。治疗后2组患者血清MMP-9表达均降低，观察组患者MMP-9表达低于对照组(P<0.05)；治疗后观察组患者TIMP-1表达未出现显著波动（P>0.05），但对照组患者TIMP-1表达升高(P<0.05)。治疗后，2组QOL评分均下降，差异有统计学意义(P<0.05)，其中观察组QOL评分下降幅度大于对照组，差异有统计学意义(P<0.05)。观察组患者不良反应发生率为9.84%，对照组为24.59%，观察组患者不良反应发生率低于对照组(P<0.05)。结论：对于晚期非小细胞肺癌患者在吉非替尼治疗基础上加用参一胶囊能够降低患者由化疗药物引起的不良反应，提高患者的生命质量，并且能够降低患者血清MMP-9的表达，利于延缓肿瘤细胞的侵袭、转移。 |
| English Summary: |
| To observe the effecta of Shenyi capsule combined with gefitinib on serum MMP-9 in patients with advanced non-small cell lung cancer.Methods:A total of 126 NSCLC patients admitted to our hospital from March 2015 to January 2017 were randomly divided into observation group (Shenyi capsule+gefitinib) and control group (gefitinib Nigeria).After 60 days of treatment, the clinical efficacy of the two groups were compared, and the changes of serum MMP-9 and TIMP-1, the quality of life (QOL) before and after treatment were compared.Based on the WHO classification of common toxicity of chemotherapy drugs, the occurrence of patients and drug-related serious adverse reactions (III, IV) were recorded.Results:The total remission rate was 63.93% in the observation group and 55.74% in the control group.There was no significant difference between the two groups (P>0.05).After treatment, the expression of MMP-9 in the observation group and the control group decreased significantly, while the expression of MMP-9 in the observation group was lower than that in the control group (P<0.05).There was no significant change in the expression of TIMP-1 in the observation group, but TIMP-1 expression was increased in the control group (P<0.05).After treatment, the QOL scores decreased in both groups, with significant difference (P<0.05).The QOL score in observation group decreased more than that in control group (P<0.05).The incidence of adverse reactions in the observation group was 9.84% and in the control group was 24.59%.The incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05).Conclusion:Adding Shenyi Capsule to gefitinib in patients with advanced non-small cell lung cancer can reduce adverse reactions caused by chemotherapeutic drugs, improve patients' quality of life and reduce the serum MMP-9 expression, which can help to delay the invasion and metastasis of tumor cells. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
